The introduction about Levodopa and the demonstration that dopamine loss is the key pathological feature of PD have revolutionized the field of PD therapeutics. In most cases of Parkinson’s disease, protein deposits called Lewy Bodies. It is unclear whether Lewy bodies play an important role in killing nerve cells or just part of the cells which are responsible to the Parkinson’s disease. Nearly 15 percent of people with PD have motor symptoms that are not controlled with levodopa. A group of drugs that act directly on dopaminergic reports called dopamine against is used as adjuncts to levodopa in the treatment of PD.
Related: Parkinson’s Conference | Parkinson’s Congress | Parkinson’s Disorder Congress | Movement Disorder Conferences | Neuroscience Conference | Neurology Conference
Related Conferences:
6th World Congress on Parkinson’s & Huntington Disease, September 20-21, 2020 at Rome, Italy | International Congress of Parkinson's Disease and Movement Disorders, September 13-17, 2020, at Philadelphia, USA | 6th World Parkinson Congress, June 7-10, 2022 at Barcelona, Spain | 7th International Congress on Parkinson's and Movement Disorders, November 14-15, 2019 at London, UK | 29th World Congress on Neurology and Therapeutics, February 24-25,2020 at London, UK
Related Association and Societies:
American Academy of Neurology; Movement Disorders Society; The International Parkinson and Movement Disorder Society; Canadian Movement Disorders Group; UK Parkinson’s Action Network; European Neurological Society; European Parkinson’s Disease Association; Danish Movement Disorder Society; Italian Society for the study of Parkinson Disease; Extrapyramidal Diseases and Dementia; Movement Disorder Society of Australia; Parkinson’s Disease and Movement Disorders Society of India; Australian Parkinson’s Disease Society; Movement Disorder Society of Japan
All accepted abstracts will be published in respective Allied Academies Journals.
Abstracts will be provided with Digital Object Identifier by
